APIs ARE THE KEY TO CAMBER’S ROBUST PIPELINE AND STRONG SUPPLY CHAIN
The parent company of Camber Pharmaceuticals, Inc, Hetero Drugs, is India’s largest supplier of active pharmaceutical ingredient (API) products, with 25 years of experience in developing APIs across diverse therapeutic areas. In fact, Camber is one of the first Indian companies to develop and manufacture affordable APIs for antiretroviral therapy (ARV). The company’s portfolio spans more than 300 APIs that encompass various segments. Hetero’s 11 exclusive manufacturing units are vertically integrated and have large-scale production capabilities that allow the company to produce bulk APIs for regulated and semiregulated markets. Hetero’s API facility in Nakkapalli, India, is Asia’s largest, situated on 500 acres with more than 1250 reactors in operation. Hetero has the distinction of being the largest global supplier of ARV drugs. It is also a world leader in the development and manufacturing of finished formulations, with a wide portfolio of more than 200 products across various therapeutic categories, such as cardiovascular, HIV/AIDS, neurology, and oncology.

RESEARCH AND DEVELOPMENT IS HETERO’S GREATEST STRENGTH
Staffed by more than 1000 top-notch scientists with a wealth of experience and knowledge, Hetero’s research and development (R&D) division has produced biosimilar products, complex APIs, new chemical entities, niche generics, and novel drug delivery systems. Numerous abbreviated new drug applications, patents, and patent cooperation treaties showcase Hetero’s strength in R&D.

CAMBER IS FOCUSED ON THE FUTURE OF GENERICS
Camber is building on Hetero’s strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development, and commercialization. Camber is slated to launch some 20 products in the next calendar year. With 2.5 million square feet of manufacturing space, Camber and Hetero can effortlessly scale up to meet significant product quantity demands.
 
For more information, visit camberpharma.com.